Myocardial bridge (MB) is a congenital anomaly of epicardial circulation characterized by an intramural course of a coronary segment. This anatomical arrangement causes the artery to be squeezed during systole potentially causing flow impairment and ischemia. For this study, MB is defined as the presence of systolic compression in an epicardial vessel causing at least 50% of caliber reduction from diastole. MB can be disabling as it worsens the quality of life. Early detection of this congenital condition is crucial, and an invasive functional assessment of the ischemic burden should be considered to evaluate the need for medical or surgical therapy. This is an observational study, involving four Italian centres. Study Objectives are: To assess the risk of future cardiovascular complications in patients with MB referred for coronary angiography and the role of beta-blocker therapy; To describe the clinical and anatomical characteristics of patients presenting with MB; To determine the impact of cardiovascular medications on symptoms in patients with MB; To describe the anatomical and clinical features associated with the invasive evidence of ischemia in patients with MB; To assess the relation between invasively documented ischemia and clinical manifestations in patients with the MB. Inclusion Criteria: patients referred to undergo ICA (for both elective or urgent indications) for suspected coronary artery disease found to have an MB with or without other epicardial lesions amenable to revascularization; Age above 18 y.o.; Ability to provide Informed Consent. Exclusion Criteria are Patients with life expectancy below 12 months and Patients with severe valvular heart disease. The primary endpoint is the incidence of MACE defined as the composite of cardiac death, myocardial infarction, cardiac hospitalization, and target vessel revascularization. The secondary endpoint is evaluating the Rate of patients with SAQ \< 70 and the Rate of patients with "high-risk features" on CT scan.
Study Type
OBSERVATIONAL
Enrollment
444
Arcispedale S. Anna, Azienda Ospedaliero - Universitaria di Ferrara
Ferrara, Italia, Italy
Policlinico S. Martino IRCCS, Università di Genova
Genova, Italia, Italy
Centro Cardiologico Monzino IRCCS
Milan, Italia, Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Roma, Italia, Italy
Policlinico Universitario Tor Vergata Fondazione PTV
Roma, Italy
Incidence of MACE
Incidence of MACE defined as the composite of cardiac death, myocardial infarction, cardiac hospitalization and target vessel revascularization
Time frame: 2 years follow up
Rate of patients with SAQ < 70
Time frame: 2 years follow up
Rate of patients with "high risk features" on CT scan
High risk features
Time frame: 2 years follow up
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.